<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159104</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-TD-005</org_study_id>
    <nct_id>NCT03159104</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children</brief_title>
  <official_title>Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study:

        -  To assess efficacy of Tenoten for children® in children with specific developmental
           disorders of scholastic skills.

        -  To assess safety of Tenoten for children® in children with specific developmental
           disorders of scholastic skills.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean total scholastic ability score (reading, spelling and counting) in patient groups at 12 weeks compared to baseline</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean score on the Reading Skills test in patient groups at 12 weeks compared to baseline</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score on the Writing Skills test in patient groups at 12 weeks compared to baseline</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score on the WISC Arithmetic subset (III) in patient groups at 12 weeks compared to baseline</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of children with an improvement total scholastic ability score (reading, spelling and counting) at 12 weeks compared to baseline</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression score (on CGI-EI) by the end of treatment</measure>
    <time_frame>in 12 weeks of the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Scholastic Skills Development Disorders</condition>
  <arm_group>
    <arm_group_label>Tenoten for children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenoten for children</intervention_name>
    <description>Safety and Efficacy</description>
    <arm_group_label>Tenoten for children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficacy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children of both sexes aged from 7 to 9 years.

          2. First to third grade students (1st-graders will be enrolled at the beginning of the
             second academic semester) at state-accredited secondary schools following the general
             elementary education program in compliance with Russia's National Federal Educational
             Standard.

          3. Beginning of the second academic semester (only for 1st-graders).

          4. Specific developmental disorder of scholastic skills such as:

               -  specific reading disorder (F81.0);

               -  specific spelling disorder (F81.1);

               -  specific disorder of arithmetical skills (F81.2);

               -  mixed disorder of scholastic skills (F81.3; i.e. meeting the criteria for one of
                  the following combinations: F81.2+F81.0, F81.2+F81.1, or F81.2+F81.0+F81.1).

          5. Reading score of 15 to 35 on the Reading Skills test (L.A. Fotekova, T.V. Akhutina,
             2002).

          6. Writing score of 15 to 30 on the Writing Skills test (L.A. Fotekova, T.V. Akhutina,
             2002).

          7. Counting score of 5 to 15 on the WISC (subtest III - Arithmetic).

          8. Availability of a patient information sheet (Informed Consent form) signed by the
             patient's parent(s)/adopter(s) to confirm the child's participation in the clinical
             trial signed by one parent/adopter of patient.

        Exclusion Criteria:

          1. Prior medical diagnoses:

               -  Diseases of the nervous system, including

                    -  inflammatory diseases of the central nervous system;

                    -  systemic atrophies;

                    -  extrapyramidal and movement disorders;

                    -  degenerative diseases of the nervous system;

                    -  demyelinating diseases of the central nervous system;

                    -  episodic and paroxysmal disorders;

                    -  polyneuropathies;

                    -  diseases of myoneural junction and muscle;

                    -  cerebral palsy.

               -  Congenital malformations of the nervous system (excl. Spina bifida without
                  hydrocephalus)

               -  Diseases and congenital malformations of eye causing impairment of vision.

               -  Diseases and congenital malformations of ear causing impairment of hearing.

               -  Organic mental disorders.

               -  Mental retardation ranging from mild to profound.

               -  Stuttering (stammering).

               -  Obsessive-compulsive disorder.

               -  Pervasive developmental disorders including:

                    -  childhood autism;

                    -  atypical autism;

                    -  Rett syndrome;

                    -  overactive disorder associated with mental retardation and stereotyped
                       movements;

                    -  Asperger syndrome.

               -  Phakomatoses (tuberous sclerosis, neurofibromatosis).

               -  Postconcussional syndrome.

               -  Hereditary metabolic diseases, including glycogen storage disease (glycogenoses),
                  disorders of galactose metabolism (galactosaemia), other disorders of
                  carbohydrate metabolism, disorders of glycosaminoglycan metabolism
                  (mucopolysaccharidoses), disorders of aromatic amino-acid metabolism
                  (phenylketonuria, tyrosinaemia etc.), disorders of branched-chain amino-acid
                  metabolism and fatty-acid metabolism (maple-syrup-urine disease), mitochondrial
                  myopathy.

               -  Chromosomal abnormalities.

          2. Intake of medicines listed in the section 'Prohibited concomitant treatment' for 4
             weeks prior to the enrollment in the trial.

          3. Need to administer drugs for the underlying disease and/or comorbid condition in the
             following 12 weeks.

          4. Acute infectious disease or exacerbation/decompensation of a disease affecting
             patient's ability to participate in the trial.

          5. Malignant neoplasm/suspected malignant neoplasm.

          6. Allergy/intolerance to any of the components of medications used in the treatment.

          7. Malabsorption syndrome including congenital or acquired lactase deficiency (or another
             disaccharidase deficiency), galactosemia.

          8. Mental disorders of patient's parent(s)/adopter(s).

          9. Drug addiction, alcohol use in the amount over 2 units of alcohol a day by the
             patient's parent(s)/adopter(s).

         10. Participation in other clinical studies within 3 months prior to inclusion in this
             trial.

         11. Patients whose parent(s)/adopter(s), from the investigator's point of view, will fail
             to comply with the observation requirements of the trial or with the dose regimen of
             the investigational drug.

         12. Patients whose parent/adopter is related to the clinical site's research staff
             directly involved in the trial, or is the immediate family member of the researcher.
             The immediate family members include husband/wife, parents, children or brothers (or
             sisters), regardless of whether they are natural or adopted.

         13. Patients whose parent(s)/adopter(s) work for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e.,
             is the company's employee, temporary contract worker or appointed official responsible
             for carrying out the research or their immediate family).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Sverdlovsk Region Children's Clinical Hospital of Rehabilitation The Scientific and Practical Center &quot;Bonum&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elmira Sagutdinova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elmira Sagutdinova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The State Budgetary Healthcare Institution &quot;Specialized Clinical Psychiatric Hospital No. 1&quot; of the Krasnodar Region Health Department</name>
      <address>
        <city>Krasnodar</city>
        <zip>350007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Bojchevskaya</last_name>
    </contact>
    <investigator>
      <last_name>Yuliya Bojchevskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Pirogov Russian National Research Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaj Zavadenko, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Nikolaj Zavadenko, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moscow Regional Research and Clinical Institute (&quot;MONIKI&quot;)</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Panteleeva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Panteleeva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;NIZHMEDCLINIKA&quot;</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603159</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Haleckaya, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olga Haleckaya, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC City Neurological Center &quot;Sibneyromed&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Doronina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Doronina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Research and Clinical Center for Infectious Diseases</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Skripchenko, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Natalya Skripchenko, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
    <mesh_term>Learning Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

